Kamada (NASDAQ:KMDA) Now Covered by StockNews.com

Posted by on Jun 8th, 2023

StockNews.com initiated coverage on shares of Kamada (NASDAQ:KMDA – Get Rating) in a research report issued on Thursday. The brokerage set a “buy” rating on the biotechnology company’s stock.

Separately, HC Wainwright reissued a “buy” rating and issued a $11.00 price target on shares of Kamada in a research report on Thursday, March 16th.

Kamada Price Performance

Shares of NASDAQ KMDA opened at $5.19 on Thursday. The company has a debt-to-equity ratio of 0.07, a current ratio of 1.90 and a quick ratio of 0.75. The company has a 50-day moving average price of $4.78 and a 200-day moving average price of $4.55. The stock has a market capitalization of $232.62 million, a P/E ratio of -103.80 and a beta of 0.98. Kamada has a 1 year low of $3.72 and a 1 year high of $5.72.

Kamada (NASDAQ:KMDA – Get Rating) last released its quarterly earnings results on Wednesday, March 15th. The biotechnology company reported $0.11 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.07 by $0.04. The business had revenue of $45.44 million during the quarter, compared to the consensus estimate of $44.64 million. Kamada had a positive return on equity of 8.15% and a negative net margin of 1.74%. On average, equities research analysts forecast that Kamada will post 0.1 EPS for the current fiscal year.

Institutional Investors Weigh In On Kamada

A number of institutional investors have recently added to or reduced their stakes in KMDA. Y.D. More Investments Ltd bought a new position in shares of Kamada in the fourth quarter valued at approximately $91,000. Susquehanna International Group LLP bought a new stake in shares of Kamada during the 4th quarter worth $41,000. Arete Wealth Advisors LLC purchased a new position in shares of Kamada in the 4th quarter worth about $949,970,200,000. Goldman Sachs Group Inc. grew its position in Kamada by 151.1% during the first quarter. Goldman Sachs Group Inc. now owns 37,518 shares of the biotechnology company’s stock valued at $208,000 after buying an additional 22,576 shares during the period. Finally, Citigroup Inc. grew its position in Kamada by 2,620.0% during the first quarter. Citigroup Inc. now owns 36,938 shares of the biotechnology company’s stock valued at $206,000 after buying an additional 35,580 shares during the period. 15.29% of the stock is owned by institutional investors.

About Kamada

(Get Rating)

Kamada Ltd. is a biopharmaceutical company, which focuses on specialty plasma-derived therapeutic. It operates through the Proprietary Products and Distribution segments. The Proprietary Products segment covers the development, manufacture, and sale of plasma-derived protein therapeutics products. The Distribution segment covers the drug products in Israel, which are manufactured by third parties.

Featured Articles

Receive News & Ratings for Kamada Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kamada and related companies with MarketBeat.com's FREE daily email newsletter.